1. Home
  2. SER vs CTSO Comparison

SER vs CTSO Comparison

Compare SER & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$3.39

Market Cap

42.0M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.72

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SER
CTSO
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.0M
49.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SER
CTSO
Price
$3.39
$0.72
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$13.00
$5.38
AVG Volume (30 Days)
17.2K
126.1K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,000.00
$36,979,520.00
Revenue This Year
$134.46
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$3.28
$0.60
52 Week High
$7.92
$1.61

Technical Indicators

Market Signals
Indicator
SER
CTSO
Relative Strength Index (RSI) 30.89 46.64
Support Level $3.68 $0.70
Resistance Level $4.26 $0.85
Average True Range (ATR) 0.26 0.07
MACD -0.02 0.01
Stochastic Oscillator 1.94 52.04

Price Performance

Historical Comparison
SER
CTSO

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: